B+
Bull case
25%
Probability
Target price
$4.75
+42.4% vs current
TLSI
TriSalus Life SciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$3.10
-7.0% vs current
B-
Bear case
30%
Probability
Target price
$1.50
-55.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+39.5
Score
AI commentary
Post-earnings tone is mixed rather than cleanly positive. Primary company materials added legitimate evidence-progress items, but the most decision-relevant new information was the lowered 2026 revenue guide and delayed TriNav Advance clearance [#PR-2026-05-12]. Secondary follow-up coverage also framed the print as a revenue dip/guidance reset story, while analyst revision visibility remains sparse and the available reaction data are noisy, so this still looks like a monitoring setup rather than a confirmed post-print turn.
RankAlpha Sentiment Codex - 2026-05-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15catalystSecond-half revenue recovery must offset the Q1 resetHigh impact
Q1 revenue was $8.9 million, down 2.9% year over year, and management revised 2026 revenue guidance to $54 million-$57 million from the prior $60 million-$62 million posture, citing commercial expansion disruption and delayed TriNav Advance FDA clearance. The next few months now matter more than usual because management described only marginal sequential Q2 improvement before a heavier Q3/Q4 ramp, so guide credibility is a live execution checkpoint rather than a settled positive [#PR-2026-05-12] [#10-Q-2026-05-12].
2026-08-31eventEarly-2H26 consolidated PERIO Phase I nelitolimod readout is still the main biotech upside eventHigh impact
TriSalus said it remains on track for a consolidated PERIO Phase I readout in the early second half of 2026 and reiterated that it intends to advance the program through a partnership structure. The 10-K had already framed 2026 data and partnering discussions as the core pipeline inflection, so this remains the clearest event catalyst, but it is still early-stage and highly data-dependent [#10-K-2026-03-05] [#PR-2026-05-12].
2026-12-31catalystPEDD evidence expansion needs to convert into durable commercial adoptionHigh impact
Management highlighted a peer-reviewed real-world PEDD study, 10 active studies across 24 sites with more than 400 TriNav-treated patients, two prospective trials beginning enrollment this quarter, and additional publication submissions targeted this quarter. That broadens the evidence base and could support institutional adoption, but the stock likely needs proof that this evidence translates into sustained account productivity and not just publication momentum [#PR-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology